Safety Reading Notes

Read safety context beside the research guide.

The Anandamide source set includes safety-context rows around anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: insufficient. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 36150527

Evidence class: insufficient

PubMed For Dummies Article

Anandamide Evidence Review: the long-form source walk-through

Quick read
  • Anandamide currently has 15 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 36150527
  • The evidence classes most visible in the row language are insufficient (11), and mechanistic or pharmacological (4). PMID 27516570
  • The study-design language most visible in the row language is Narrative or expert review (11), Cellular or in vitro study (2), and Animal study (2). PMID 22297258
  • The repeated topics are anandamide biology, receptor pharmacology, metabolism, physiology, or safety-... (15), which tells the reader where to start opening PubMed and DOI links. PMID 12052051

Start with the research question

Anandamide is built from 15 source-backed evidence row(s) and 15 research source(s). The current evidence classes read as insufficient (11), and mechanistic or pharmacological (4), and the study-design language most often reads as Narrative or expert review (11), Cellular or in vitro study (2), and Animal study (2). PMID 36150527

The row-level question is not simply whether Anandamide is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are anandamide biology, receptor pharmacology, metabolism, physiology, or safety-... (15). PMID 34126378

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 34126378

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 25461979

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 20302856

Limits and uncertainty 11 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 27100705

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 35038882

Where this page has the most source density

The largest bucket surfaced for this page is anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 36150527

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 34126378

Bucket chapters: what the literature is circling

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: insufficient

11 research sources 11 rows (1063-1077) Evidence class: insufficient

This bucket summarizes source-backed rows focused on anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: insufficient. It currently draws from 11 research source(s), so the exact study type matters. PMID 36150527

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 36150527

  • Evidence row 1063

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 36150527

  • Evidence row 1077

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 24325918

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: mechanistic or pharmacological

4 research sources 4 rows (1067, 1071, 1072, 1073) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on anandamide biology, receptor pharmacology, metabolism, physiology, or safety-...: mechanistic or pharmacological. It currently draws from 4 research source(s), so the exact study type matters. PMID 34126378

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 34126378

  • Evidence row 1067

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentio... PMID 34126378

  • Evidence row 1071

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned;... PMID 35038882

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 36150527

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 34126378

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 35986066
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 11470906
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 32867595

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 36150527

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 34126378

Source-reading checklist for Anandamide

  1. Open the linked PubMed or DOI record. PMID 32894511
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 23512546
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 24325918
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 36150527
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 27516570

Source Notes

Anandamide source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1063

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36150527

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.
  2. Evidence row 1064

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27516570

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism of endocannabinoids.
  3. Evidence row 1065

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 22297258

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide uptake explained?
  4. Evidence row 1066

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12052051

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide receptors.
  5. Evidence row 1067

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 34126378

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.
  6. Evidence row 1068

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25461979

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid metabolism by cytochrome P450 monooxygenases.
  7. Evidence row 1069

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 20302856

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and pregnancy.
  8. Evidence row 1070

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27100705

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and its metabolites: what are their roles in the kidney?
  9. Evidence row 1071

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 35038882

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Endocannabinoids.
  10. Evidence row 1072

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 35986066

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB1 receptors regulate salivation.
  11. Evidence row 1073

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 11470906

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
  12. Evidence row 1074

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32867595

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.
  13. Evidence row 1075

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32894511

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Druggable Targets in Endocannabinoid Signaling.
  14. Evidence row 1076

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23512546

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical probes of endocannabinoid metabolism.
  15. Evidence row 1077

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24325918

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Amygdala FAAH and anandamide: mediating protection and recovery from stress.